Acadia Pharmaceuticals Inc (ACAD) stock
Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –
Earnings
Acadia Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Acadia Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $342.00M | +22.8% | $0.31 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026during market hours | – | – | $0.18 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | $268.00M | +9.7% | $0.02 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026during market hours | $284.00M | +9.4% | $1.60 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025during market hours | $278.60M | +11.3% | $0.42 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $264.60M | +9.3% | $0.16 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $244.30M | +18.7% | $0.11 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025during market hours | $259.60M | +12.4% | $0.86 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | $250.40M | +18.3% | $0.20 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | $242.00M | +46.5% | $0.20 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $205.80M | +73.7% | $0.10 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024during market hours | $231.00M | +69.2% | $0.28 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $211.70M | +62.0% | -$0.40 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023during market hours | $165.20M | +22.7% | $0.01 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023during market hours | $118.50M | +2.6% | -$0.27 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023during market hours | $136.50M | +4.4% | -$0.26 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $130.70M | -0.7% | -$0.17 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | $134.60M | – | -$0.21 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $115.50M | – | -$0.70 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022during market hours | $130.80M | – | -$0.27 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021during market hours | $131.60M | – | -$0.09 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Acadia Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| DAYBUE (including all forms of trofinetide) global net product salesGAAP | FY2026 | $505.00M – $520.00M | $1.22B – $1.28B | Lowered | Nov 4, 2026 |
| Total revenuesGAAP | FY2026 | $1.24B – $1.30B | $1.22B – $1.28B | Raised | Aug 4, 2026 |
| DAYBUE net product salesGAAP | FY2026 | $460.00M – $490.00M | – | Lowered | May 6, 2026 |
| DAYBUE net product salesGAAP | FY2026 | $460.00M – $490.00M | – | Lowered | Feb 25, 2026 |
| NUPLAZID net product salesGAAP | FY2026 | $760.00M – $790.00M | – | New | May 6, 2026 |
| NUPLAZID net product salesGAAP | FY2026 | $760.00M – $790.00M | – | New | Feb 25, 2026 |
| R&D expenseGAAP | FY2026 | $325.00M – $340.00M | $385.00M – $410.00M | Lowered | Nov 4, 2026 |
| R&D expenseGAAP | FY2026 | $355.00M – $380.00M | $385.00M – $410.00M | Lowered | Aug 4, 2026 |
| SG&A expenseGAAP | FY2026 | $665.00M – $685.00M | $660.00M – $700.00M | Raised | Nov 4, 2026 |
| SG&A expenseGAAP | FY2026 | $660.00M – $700.00M | $660.00M – $700.00M | Raised | Aug 4, 2026 |
Guidance vs results
The last range Acadia Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $1.07B – $1.10B | $1.07BΣ4Q | Within range |
| Q4 FY2023 | Revenue | $80.00M – $87.50M | $231.00M | Above range |
| Q3 FY2023 | Revenue | $45.00M – $55.00M | $211.70M | Above range |
Guidance history
Every forecast Acadia Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | R&D expense | FY2026 | $325.00M – $340.00M | Lowered |
| Nov 4, 2026 | SG&A expense | FY2026 | $665.00M – $685.00M | Raised |
| Nov 4, 2026 | DAYBUE (including all forms of trofinetide) global net product sales | FY2026 | $505.00M – $520.00M | Lowered |
| Nov 4, 2026 | Total revenues | FY2026 | $1.27B – $1.30B | Raised |
| Nov 4, 2026 | NUPLAZID net product sales | FY2026 | $760.00M – $775.00M | Lowered |
| Aug 4, 2026 | SG&A expense | FY2026 | $660.00M – $700.00M | Raised |
| Aug 4, 2026 | R&D expense | FY2026 | $355.00M – $380.00M | Lowered |
| Aug 4, 2026 | Total revenues | FY2026 | $1.24B – $1.30B | Raised |
| Aug 4, 2026 | DAYBUE (including all forms of trofinetide) global net product sales | FY2026 | $480.00M – $510.00M | Lowered |
| Aug 4, 2026 | NUPLAZID net product sales | FY2026 | $760.00M – $790.00M | Lowered |
| May 6, 2026 | NUPLAZID net product sales | FY2026 | $760.00M – $790.00M | New |
| May 6, 2026 | DAYBUE net product sales | FY2026 | $460.00M – $490.00M | Lowered |
| May 6, 2026 | R&D expense | FY2026 | $385.00M – $410.00M | Lowered |
| May 6, 2026 | SG&A expense | FY2026 | $660.00M – $700.00M | Raised |
| May 6, 2026 | Total revenues | FY2026 | $1.22B – $1.28B | New |
| Feb 25, 2026 | DAYBUE net product sales | FY2026 | $460.00M – $490.00M | Lowered |
| Feb 25, 2026 | NUPLAZID net product sales | FY2026 | $760.00M – $790.00M | New |
| Feb 25, 2026 | R&D expense | FY2026 | $385.00M – $410.00M | Lowered |
| Feb 25, 2026 | SG&A expense | FY2026 | $660.00M – $700.00M | Raised |
| Feb 25, 2026 | Total revenues | FY2026 | $1.22B – $1.28B | New |
| Nov 5, 2025 | SG&A expense | FY2025 | $540.00M – $555.00M | Raised |
| Nov 5, 2025 | R&D expense | FY2025 | $335.00M – $345.00M | New |
| Nov 5, 2025 | Total Revenues | FY2025 | $1.07B – $1.10B | New |
| Nov 5, 2025 | DAYBUE net product sales | FY2025 | $385.00M – $400.00M | Lowered |
| Nov 5, 2025 | NUPLAZID net product sales | FY2025 | $685.00M – $695.00M | Lowered |
| Aug 6, 2025 | SG&A expense | FY2025 | $535.00M – $565.00M | Raised |
| Aug 6, 2025 | R&D expense | FY2025 | $330.00M – $350.00M | Lowered |
| Aug 6, 2025 | DAYBUE net product sales (U.S. only) | FY2025 | $380.00M – $405.00M | Lowered |
| Aug 6, 2025 | NUPLAZID net product sales | FY2025 | $665.00M – $690.00M | Lowered |
| Aug 6, 2025 | Total Revenues (U.S. only) | FY2025 | $1.05B – $1.10B | Raised |
| May 7, 2025 | R&D expense | FY2025 | $330.00M – $350.00M | Lowered |
| May 7, 2025 | SG&A expense | FY2025 | $535.00M – $565.00M | Raised |
| May 7, 2025 | Total Revenues (U.S. only) | FY2025 | $1.03B – $1.10B | Reaffirmed |
| May 7, 2025 | DAYBUE net product sales (U.S. only) | FY2025 | $380.00M – $405.00M | Lowered |
| May 7, 2025 | NUPLAZID net product sales | FY2025 | $650.00M – $690.00M | Lowered |
| Feb 26, 2025 | R&D expense | FY2025 | $310.00M – $330.00M | Lowered |
| Feb 26, 2025 | SG&A expense | FY2025 | $535.00M – $565.00M | Raised |
| Feb 26, 2025 | NUPLAZID net product sales | FY2025 | $650.00M – $690.00M | New |
| Feb 26, 2025 | DAYBUE net product sales (U.S. only) | FY2025 | $380.00M – $405.00M | Lowered |
| Feb 26, 2025 | Total Revenues (U.S. only) | FY2025 | $1.03B – $1.10B | New |
| Nov 6, 2024 | R&D expense | FY2024 | $280.00M – $290.00M | Lowered |
| Nov 6, 2024 | SG&A expense | FY2024 | $480.00M – $495.00M | Raised |
| Nov 6, 2024 | NUPLAZID net product sales | FY2024 | $600.00M – $610.00M | Lowered |
| Nov 6, 2024 | Total revenue | FY2024 | $940.00M – $960.00M | Raised |
| Nov 6, 2024 | DAYBUE net product sales | FY2024 | $340.00M – $350.00M | Lowered |
| Aug 6, 2024 | NUPLAZID net product sales | FY2024 | $590.00M – $610.00M | Raised |
| Aug 6, 2024 | DAYBUE net product sales | FY2024 | $340.00M – $370.00M | Lowered |
| Aug 6, 2024 | R&D expense | FY2024 | $305.00M – $315.00M | Lowered |
| Aug 6, 2024 | SG&A expense | FY2024 | $465.00M – $480.00M | Raised |
| Aug 6, 2024 | Total revenue | FY2024 | $930.00M – $980.00M | Raised |
| May 8, 2024 | R&D expense | FY2024 | $305.00M – $325.00M | New |
| May 8, 2024 | SG&A expense | FY2024 | $455.00M – $480.00M | Raised |
| May 8, 2024 | NUPLAZID net product sales | FY2024 | $560.00M – $590.00M | Raised |
| May 8, 2024 | DAYBUE net product sales | FY2024 | $370.00M – $420.00M | Lowered |
| Feb 27, 2024 | GAAP R&D expense | FY2024 | $305.00M – $325.00M | New |
| Feb 27, 2024 | GAAP SG&A expense | FY2024 | $455.00M – $480.00M | Raised |
| Feb 27, 2024 | DAYBUE net product sales | FY2024 | $370.00M – $420.00M | New |
| Feb 27, 2024 | NUPLAZID net product sales | FY2024 | $560.00M – $590.00M | Raised |
| Nov 2, 2023 | R&D expense | FY2023 | $340.00M – $350.00M | Lowered |
| Nov 2, 2023 | SG&A expense | FY2023 | $390.00M – $400.00M | Raised |
| Nov 2, 2023 | DAYBUE net sales | Q4 FY2023 | $80.00M – $87.50M | New |
| Nov 2, 2023 | NUPLAZID net sales | FY2023 | $537.50M – $545.00M | Raised |
| Aug 2, 2023 | R&D expense | FY2023 | $335.00M – $355.00M | Lowered |
| Aug 2, 2023 | SG&A expense | FY2023 | $380.00M – $400.00M | Raised |
| Aug 2, 2023 | DAYBUE third quarter net sales | Q3 FY2023 | $45.00M – $55.00M | New |
| Aug 2, 2023 | NUPLAZID full year net sales | FY2023 | $530.00M – $545.00M | Narrowed |
| May 8, 2023 | R&D expense | FY2023 | $235.00M – $255.00M | New |
| May 8, 2023 | SG&A expense | FY2023 | $360.00M – $380.00M | Raised |
| May 8, 2023 | NUPLAZID net sales | FY2023 | $520.00M – $550.00M | Reaffirmed |
| Feb 27, 2023 | R&D expense | FY2023 | $235.00M – $255.00M | New |
| Feb 27, 2023 | SG&A expense | FY2023 | $360.00M – $380.00M | Raised |
| Feb 27, 2023 | Net NUPLAZID sales | FY2023 | $520.00M – $550.00M | New |
| Nov 2, 2022 | GAAP R&D | FY2022 | $345.00M – $355.00M | Lowered |
| Nov 2, 2022 | GAAP SG&A | FY2022 | $365.00M – $375.00M | Raised |
| Nov 2, 2022 | NUPLAZID net sales | FY2022 | $510.00M – $520.00M | Lowered |
| Aug 8, 2022 | GAAP R&D | FY2022 | $340.00M – $360.00M | Lowered |
| Aug 8, 2022 | GAAP SG&A | FY2022 | $360.00M – $380.00M | Raised |
| Aug 8, 2022 | NUPLAZID net sales | FY2022 | $510.00M – $540.00M | Lowered |
| May 4, 2022 | GAAP R&D | FY2022 | $355.00M – $375.00M | Lowered |
| May 4, 2022 | GAAP SG&A | FY2022 | $360.00M – $380.00M | Raised |
| May 4, 2022 | NUPLAZID net sales | FY2022 | $510.00M – $560.00M | Reaffirmed |
| Feb 28, 2022 | GAAP R&D guidance | FY2022 | $355.00M – $375.00M | New |
| Feb 28, 2022 | GAAP SG&A guidance | FY2022 | $360.00M – $380.00M | Raised |
| Feb 28, 2022 | NUPLAZID net sales guidance in Parkinson’s disease psychosis | FY2022 | $510.00M – $560.00M | New |
| Nov 8, 2021 | GAAP R&D | FY2021 | $230.00M – $245.00M | New |
| Nov 8, 2021 | GAAP SG&A | FY2021 | $385.00M – $405.00M | Raised |
| Nov 8, 2021 | NUPLAZID net sales | FY2021 | $480.00M – $500.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Acadia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?